Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature.

Date publication

avril 2017

Journal

Autoimmunity reviews

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARTIN Thierry

Tous les auteurs :
Sanges S, Rivière S, Mekinian A, Martin T, Le Quellec A, Chatelus E, Lescoat A, Jego P, Cazalets C, Quéméneur T, Le Gouellec N, Senet P, Francès C, Deroux A, Imbert B, Fain O, Boukari L, Sené T, Deligny C, Mathian A, Agard C, Pugnet G, Speca S, Dubucquoi S, Hatron PY, Hachulla É, Launay D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28232167

Résumé

As intravenous immunoglobulins (IVIG) exhibit immunomodulatory and antifibrotic properties, they may be a relevant treatment for systemic sclerosis (SSc). The objectives of this work were thus to report on the efficacy and safety of IVIG in a population of SSc patients and to review the available literature.

Mots clés

Fibrosis, Inflammatory myopathies, Intravenous immunoglobulins, Systemic sclerosis

Référence

Autoimmun Rev. 2017 Apr;16(4):377-384